An argument for the past and continued use of pentoxifylline in assisted reproductive technology

• Published in: Human reproduction (Oxford) 1995-10, Vol.10 (suppl-1), p.67-71
• Main Authors: Matson, Phillip L., Yovich, Jeanne M., Edirisinghe, W.Rohini, Junk, Stephen M., Yovich, John L.
• Format: Article
• Language: English
• Subjects: assisted reproductive technology; Biological and medical sciences; Birth control; Fertilization - drug effects; Fertilization in Vitro - trends; Gynecology. Andrology. Obstetrics; Humans; Infertility, Male - therapy; Insemination, Artificial; IVF; Male; Medical sciences; pentoxifylline; Pentoxifylline - therapeutic use; Spermatozoa - drug effects; Sterility. Assisted procreation
• ISSN: 0268-1161; 1460-2350
• DOI: 10.1093/humrep/10.suppl_1.67

Pentoxifylline was first used within an in-vitro fertilization (IVF) programme before the advent of alternative treatment strategies such as oocyte micromanipulation. Over the years, it has continued to be useful in aiding fertilization in selected IVF cases, with a beneficial effect also being seen in certain cases treated by intrauterine insemination. In both instances, the acrosome reaction to ionophore challenge test appears to have been invaluable in identifying suitable patients. The stimulation of spermatozoa by pentoxifylline should remain a therapeutic option in the treatment of couples with a male factor present. As an adjunct to IVF, it has the advantage of being simpler and less costly to perform compared with micromanipulation. However, its use should be restricted to selected cases, and the merits over and above those of invasive procedures such as intracytoplasmic sperm injection should be discussed with the individual patients. The pretreatment of spermatozoa prior to intrauterine insemination in selected cases gives an alternative therapeutic strategy to those patients not wishing or unable to undertake IVF.